Bracco Imaging subsidiary Blue Earth Therapeutics has closed on $76.5 million in a series A financing round.
The funds will support phase II studies of the company’s experimental theranostic radiopharmaceuticals for imaging and treating prostate cancer, the company said. Blue Earth has developed a radiohybrid (rh) prostate-specific membrane antigen (rhPSMA-10.1) ligand that targets PSMA receptors on cancer cells. The ligand can be labeled with isotopes such as F-18 or gallium-68 for PET imaging and with lutetium-177 and actinium-225, which destroy DNA in cancer cells at the site of tumors.
The funding round was led by Soleus Capital and co-led by Sands Capital Management, with existing investor Bracco Imaging also participating, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
